Festival of Biologics: Biosimilars set for bright future in EU

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Scyther5)
(Image: Getty/Scyther5)

Related tags: Biosimilars, European union, Us, Market access

During this year’s Festival of Biologics conference, one track saw a focus on biosimilars that brought together experts from across the industry to map the future for such treatments in the EU and US.

BioPharma-Reporter was present at this year’s Festival of Biologics, which closed yesterday and was held in Basel, Switzerland, to witness the varied discussion that took place across the event’s focus on biosimilars, immunotherapies, and antibodies.

During sessions on biosimilars, speakers highlighted current uptake levels in the European Union (EU), making case studies of particular countries, such as Scotland, whilst also pointing to the outlook in the US – which has been notably slower to adopt such technology.

For BioPharma-Reporter’s insights and those of fellow attendees, see below:

Related news

Follow us

Products

View more

Webinars